The drug approval process is an often complex and complicated process which involves the preclinical discovery and screening of potential new drugs, different phases of clinical trials, and regulatory approval processes including reviews and ongoing safety monitoring. Furthermore, the drug approval process varies from country to country, with the different authorities, such as the EMA, the US Food and Drug Administration (FDA), or the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, each having their own drug approval requirements.
At each stage of the drug approval process, different marketing and communication strategies need to be successfully implemented. Notably, insights from HCPs’ online conversations can help you not only develop these strategies but help you track their response. For example, by listening to and engaging with online HCP influencers or Digital Opinion Leaders at congresses during the clinical trial stage of the drug approval process, you can adapt your messaging to your target customers well before the approval and launch into the market. Furthermore, by seeking early input on target product profiles, you may be able to incorporate it into later clinical trial designs.
Finally it’s time for the #DESTINYbreast04 trial at #ASCO22 plenary session: so excited to be in the 2nd row of this big room to see such unprecedented results in the #BreastCancer field…this will remain one of the most important moment in the history of this disease@OncoAlert pic.twitter.com/VlV2bJUxEF
— Matteo Lambertini, MD PhD (@matteolambe) June 5, 2022
Alongside pharmaceutical companies opting for smaller targeted drug launches, the market has been transformed by social media – with HCPs and patients learning about treatments and innovations faster than ever before, and having a global space to share their thoughts and opinions. Therefore, the business model for launching a new drug has shifted.
Notably, the ability to distil and analyse conversations among HCPs on social media gives business intelligence teams new tools to inform pharmaceutical launch strategies. Ultimately, when you listen to your HCP customers throughout the launch period, you gain a deeper understanding of their needs, which allows you to create early awareness and advocacy, to address unmet needs and differentiate yourself from your competitors, and can accelerate market access.
HCPs are uniquely positioned to recognise gaps in a treatment landscape – this is evident in their discussions of news regarding clinical developments, the sharing of data, or even the occasional outburst of frustration. Furthermore, in an era when digital has become the new normal, the unique opportunity of digital should be leveraged to the fullest extent. Herein lies an opportunity to build an impactful marketing strategy that directly responds to the voice of the customer.
It is likely that HCPs are shaping their perceptions of your product well before you have developed your brand strategy. Thus, when thinking about content planning in a drug launch strategy it is essential that you are speaking the right message and using the language that your customers are already using on a regular basis.
Therefore, by using a market-led approach, and listening to HCP conversations on social media you are able to not only identify their needs and concerns about your product or therapy area, but you are able to hear and learn the language that they use. These invaluable insights are then able to help inform and drive your content strategy, and allow for the development of engaging and targeted content through the drug launch process.